Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Dermatological Research
Published in: Archives of Dermatological Research 1/2003

01-04-2003 | Original Paper

Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity

Authors: Y. Umezawa, A. Ozawa, T. Kawasima, H. Shimizu, T. Terui, H. Tagami, S. Ikeda, H. Ogawa, A. Kawada, T. Tezuka, A. Igarashi, S. Harada

Published in: Archives of Dermatological Research | Special Issue 1/2003

Login to get access

Abstract

Generalized pustular psoriasis (GPP) is a rare but notoriously recalcitrant cutaneous diseases. Therefore, there have been few reports of more than ten patients with GPP who were treated at the same institution. The severity of this disease and its response to each therapeutic modality vary among patients. In some GPP is life-threatening, but in others it may show a benign, chronic course for a long period of time. Before starting treatment, a knowledge of the therapeutic efficacy and side effects of each drug used in the treatment of GPP is necessary. In our multicenter study, we compared the effectiveness of and adverse reactions to several systemically administered drugs. Following the development of a unique classification of the disease severity based on scoring the clinical symptoms and the laboratory findings, we propose here therapeutic guidelines for the treatment of GPP.
Appendix
Available only for authorised users
Literature
1.
Ohkawara A (1989) A report of the MHW Investigation and Research Team in Specific and Rare Refractory Skin Diseases in 1988 (in Japanese). Ministry of Health, Labor and Welfare, Tokyo, p 9
2.
Inaba Y (1997) Comparison by published data. In: Inaba Y, Ono Y (eds) Descriptive epidemiology of pustular psoriasis/intractable diseases. Investigation Team of Epidemiology in Specific Diseases, MHLW Investigation and Research in Specific Diseases (in Japanese). Ministry of Health, Labor and Welfare, Tokyo, 206–208
3.
Ohkawara A, Yasuda H, Kobayashi H, et al (1996) Generalized pustular psoriasis in Japan; two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol 76:68–71PubMed
4.
Ohkawara A, Kobayashi H, Nishikawa K, et al (1995) Fatal generalized pustular psoriasis—to discuss causes of death and treatment points. A Report of the MHW Investigation and Research Team in Specific and Rare Refractory Skin Diseases in 1994 (in Japanese). Ministry of Health, Labor and Welfare, Tokyo, pp 123–128
5.
Ohkawara A (1998) To propose the diagnostic criteria for severity rating of pustular psoriasis. A Report of the MHW Investigation and Research Team in Specific and Rare Refractory Skin Diseases in 1997. Ministry of Health, Labor and Welfare, Tokyo, pp 44–45
6.
Ohkawara A, Kobayashi H, Kawashima T, et al (1996) Research of pustular psoriasis in Japan: type of diseases and pathology. A Report of the MHW Investigation and Research Team in Specific and Rare Refractory Skin Diseases in 1995. Ministry of Health, Labor and Welfare, Tokyo, pp 157–162
7.
Ozawa A, Ohkido M, Haruki Y, et al (1999) Treatments of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol 26:141–149PubMed
8.
Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin A and FK506. Immunol Today 13:136–142PubMed
9.
Nakagawa H (1994) Cyclosporin guidelines for psoriasis in Japan. In: Ishibashi Y, Okido M, Harada S (eds) Psoriasis and cyclosporin (in Japanese). Kokusai Igaku Syuppan, Tokyo, pp 121–126
10.
Novartis Pharma (2000) Neoral monograph: nephrotic syndrome, psoriasis, Behçet disease, aplastic anemia. Novartis, Tokyo
11.
Boffa MJ, Chalmers RJ (1996) Methotrexate for psoriasis. Clin Exp Dermatol 21:399–408
12.
Einstein GD, Frost P (1968) Abnormal cell proliferation in psoriasis. J Invest Dermatol 50:254–259
13.
Gelfant S (1983) Psoriasis versus cancer: adaptive versus iatrogenic human cell proliferative diseases. Int Rev Cytol 81:145–162PubMed
14.
Ohkawara A (1978) Methotrexate and psoriasis therapy (in Japanese). Rinsho Derm (Tokyo) 20:789–794
15.
Williams REA (1991) Guidelines for management of patients with psoriasis. BMJ 303:829–835PubMed
16.
Yoshikawa Y, Etou T, Kobayashi H, et al (2000) Guidelines of PUVA therapy on psoriasis (in Japanese). Jpn J Dermatol 110:807–814
17.
Kilic SS, Hacimustafaoglu M, Celebi S, Karadeniz A, Ildirim I (2001) Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol 18:246–248CrossRefPubMed
18.
Furukawa F, Sakaguchi J, Sakurane M, et al (2000) Immunosuppressant therapy for childhood intractable rare skin diseases. J Pediatr Dermatol 19:153–158
19.
Yu HJ, Park JW, Park JM, et al (2001) A case of childhood generalized pustular psoriasis treated with dapsone. J Dermatol 28:316–319PubMed
20.
Sugai J, Ozawa A, Kawakubo Y, et al (1998) New method for determining prognosis of patients with psoriasis (E-PAP). J Dermatol Sci 16:165–169CrossRefPubMed
21.
Kurosawa M. Inada Y, Ohkawara A, et al (1999) A case control study of pustular psoriasis using pooled controls. Jpn J Dermatol 109:1461–1469
Metadata
Title
Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity
Authors
Y. Umezawa
A. Ozawa
T. Kawasima
H. Shimizu
T. Terui
H. Tagami
S. Ikeda
H. Ogawa
A. Kawada
T. Tezuka
A. Igarashi
S. Harada
Publication date
01-04-2003
Publisher
Springer-Verlag
Published in
Archives of Dermatological Research / Issue Special Issue 1/2003
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-002-0371-6

Other articles of this Special Issue 1/2003

Archives of Dermatological Research 1/2003 Go to the issue

Original Paper

Epidermolysis bullosa: directions for future research and new challenges for treatment

Original Paper

Pathophysiology of generalized pustular psoriasis

Original Paper

History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan

Original Paper

Generalized pustular psoriasis: strategy for identification of psoriasis susceptibility gene

Original Paper

Genetic abnormalities and clinical classification of epidermolysis bullosa

Original Paper

Current status and future prospects of gene therapy technologies toward the treatment of intractable skin diseases